Nemucore Medical Innovations, Inc. Appoints Daniel E. Geffken as Interim Chief Financial Officer

 
 
Spread the Word
Listed Under

Tags:
Nemucore
Nmi
Targeted Therapeutics
Multidrug Resistant Cancer
Nemucore Medical Innovations

Industrys:
Biotech
Medical

Location:
Worcester - Massachusetts - US

WORCESTER, Mass. - June 15, 2015 - PRLog -- Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of molecularly targeted therapies to treat multidrug resistant cancers, today announced the appointment of Daniel E. Geffken, M.B.A. as its Interim Chief Financial Officer. “We are thrilled to have Dan join Nemucore’s growing team. His extensive financial experience and leadership will greatly benefit Nemucore,” said Timothy P. Coleman, President and Chief Executive Officer of Nemucore. “Dan has been the CFO of public and private life sciences companies and has the background to help develop the effective financial strategies to capitalize Nemucore’s rapid growth.”

Mr. Geffken is a Founder and Managing Director of Danforth Advisors, a consulting firm specializing in providing financial and strategic support to life sciences companies. He brings more than 22 years of experience in the life science industry, ranging from early start-ups to publicly traded companies with $1 billion+ market capitalizations. Previously, he served as COO or CFO of four publicly traded and four privately held companies and was interim CEO of a medical device company. Daniel has assisted in raising more than $1 billion in equity and debt securities. He serves on the Board of Directors for Alcobra Ltd., a biopharmaceutical company that completed an initial public offering in May 2013. He has a B.S. in Economics from The Wharton School, University of Pennsylvania and a M.B.A. from Harvard Business School.

About Nemucore Medical Innovations

Nemucore Medical Innovations, Inc. is a privately held biopharmaceutical clinical-stage oncology company developing innovative therapeutics, with a focus on treating multi-drug resistant cancers. Nemucore's most advanced product NMI-900, a "Best-In-Class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in late 2015. Two additional therapeutics are anticipated to begin clinical trials in 2016 targeting further oncology indications, including breast cancer.  For more information visit our website www.nemucore.com

Forward Looking Statement

This press release makes forward-looking statements regarding future events and our future performance about the Company’s strategy, future plans and prospects, including statements regarding the development of the Company’s therapeutic programs, the timeline for clinical development and regulatory approval of the Company’s compounds, the structure of the Company’s planned clinical trials, the Company’s rights to develop or commercialize its products, the Company’s obligations to make milestone payments and royalties and the ability of the Company to finance contemplated development activities. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “proposed,” and other similar expressions generally identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements entail various significant risks and uncertainties that could cause our actual results to differ materially from those expressed in such forward-looking statements. Applicable risks and uncertainties include the risks that the preclinical testing of the Company’s compounds may not be predictive of the success of later clinical trials, that the Company may be unable to successfully complete the clinical development of its products, that the development of the Company’s products may take longer or cost more than planned, and that the Company’s products may not receive regulatory approval or become commercially successful products. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not intend to update any of the information contained in any forward-looking statement, except as required by law. More information about the risks and uncertainties faced by Nemucore Medical Innovations, Inc. is contained in the company’s periodic reports filed with the Securities and Exchange Commission. Nemucore Medical Innovations, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
End
Source:Nemucore Medical Innovations, Inc.
Email:***@nemucore.com Email Verified
Tags:Nemucore, Nmi, Targeted Therapeutics, Multidrug Resistant Cancer, Nemucore Medical Innovations
Industry:Biotech, Medical
Location:Worcester - Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Nemucore Medical Innovations PRs
Trending News
Top Daily News
Top Weekly News



Like PRLog?
9K2K1K
Click to Share